Download Files:
Navacaprant
$385 – $2,200
Products Details
Product Description
– Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.
Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy[1].
Web ID
– HY-124754
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C25H32FN5O2
References
– [1]Guerrero M, et al. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J Med Chem. 2019 Feb 28;62(4):1761-1780.
CAS Number
– 2244614-14-8
Molecular Weight
– 453.55
Compound Purity
– 99.71
SMILES
– CC1=NOC(C2=C(C)C3=CC(CC)=CC(F)=C3N=C2N4CCC(NC5CCOCC5)CC4)=N1
Clinical Information
– Phase 2
Research Area
– Metabolic Disease; Neurological Disease
Solubility
– DMSO : 3.85 mg/mL (ultrasonic;warming;adjust pH to 4 with HCl;heat to 60°C)
Target
– Opioid Receptor
Isoform
– δ Opioid Receptor/DOR;κ Opioid Receptor/KOR;μ Opioid Receptor/MOR
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
